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ABSTRACT
Objective Crohn’s disease (CD) is associated with
intestinal dysbiosis, altered blood T cell populations,
elevated faecal calprotectin (FC) and increased intestinal
permeability (IP). CD-associated features present in
siblings (increased risk of CD) but not in healthy
controls, provide insight into early CD pathogenesis. We
aimed to (1) Delineate the genetic, immune and
microbiological proﬁle of patients with CD, their siblings
and controls and (2) Determine which factors
discriminate between groups.
Design Faecal microbiology was analysed by
quantitative PCR targeting 16S ribosomal RNA, FC by
ELISA, blood T cell phenotype by ﬂow cytometry and IP
by differential lactulose-rhamnose absorption in 22
patients with inactive CD, 21 of their healthy siblings
and 25 controls. Subject’s genotype relative risk was
determined by Illumina Immuno BeadChip.
Results Strikingly, siblings shared aspects of intestinal
dysbiosis with patients with CD (lower concentrations of
Faecalibacterium prausnitzii (p=0.048), Clostridia cluster
IV (p=0.003) and Roseburia spp. (p=0.09) compared
with controls). As in CD, siblings demonstrated a
predominance of memory T cells (p=0.002) and elevated
naïve CD4 T cell β7 integrin expression (p=0.01)
compared with controls. FC was elevated (>50 μg/g) in
8/21 (38%) siblings compared with 2/25 (8%) controls
(p=0.028); whereas IP did not differ between siblings
and controls. Discriminant function analysis determined
that combinations of these factors signiﬁcantly
discriminated between groups (χ2=80.4, df=20,
p<0.001). Siblings were separated from controls by
immunological and microbiological variables.
Conclusions Healthy siblings of patients with CD
manifest immune and microbiological abnormalities
associated with CD distinct from their genotype-related
risk and provide an excellent model in which to
investigate early CD pathogenesis.
INTRODUCTION
Crohn’s disease (CD) causes intestinal inﬂammation,
occurs predominantly in young adults and results in
signiﬁcant morbidity and reduced quality of life. The
pathogenesis of CD is unknown, but is thought to
depend on abnormal interactions between the intes-
tinal immune system and microbiota in genetically
susceptible hosts. This model is supported by the
identiﬁcation of >130 risk loci associated with CD,1
including genes controlling microbial sensing and
immune function. Furthermore, patients with CD
exhibit altered intestinal microbiota (dysbiosis)
including reduced Firmicutes such as Clostridia
cluster IV and Faecalibacterium prausnitzii,2 and
increased Escherichia coli.3 CD is characterised
Signiﬁcance of this study
What is already known about this subject?
▸ Crohn’s disease is associated with intestinal
dysbiosis, T cell abnormalities and elevated
genetic risk.
▸ The siblings of patients with Crohn’s disease
are at increased risk of developing disease
compared with the background population.
▸ A proportion of the siblings of patients with
Crohn’s disease will have elevated faecal
calprotectin and intestinal permeability.
What are the new ﬁndings?
▸ The siblings of patients with Crohn’s disease
share some aspects of the intestinal dysbiosis
with their affected relatives such as reduced
Firmicutes including Faecalibacterium
prauznitsii which has been shown to be
relevant to clinical course of disease.
▸ The siblings of patients with Crohn’s disease
share abnormalities in T cell phenotype with
their affected relatives.
▸ Siblings of patients with Crohn’s disease can be
discriminated from healthy controls by a
combination of immunological and
microbiological factors.
How might it impact on clinical practice in
the foreseeable future?
▸ This is the ﬁrst study to assess multiple aspects
of the Crohn’s disease phenotype in patients’
unaffected siblings and healthy controls.
▸ It identiﬁes novel microbiological and
immunological factors relevant to early disease
pathogenesis.
▸ It raises the possibility of predicting the risk of
Crohn’s disease onset using multidimensional
phenotyping.
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immunologically by predominant Th1/Th17 mucosal T cell
responses,4 with alterations in peripheral T cell populations and
their expression of intestinal homing receptors such as α4β7 integ-
rin.5 6 Finally, intestinal inﬂammation in CD is associated with a
raised faecal calprotectin (FC)7 and altered intestinal permeability
(IP).8 Individual factors such as elevated FC or lower mucosal F
prausnitzii can predict natural history of CD disease.2 9 However,
the alterations noted may be a consequence of established disease.
This study aims to delineate features of individuals at risk of CD
relevant to disease pathogenesis.
First-degree relatives of patients with CD are at increased risk
of developing IBD compared with background populations.10
Monozygotic twin disease discordance highlights the import-
ance of non-genetic factors in disease pathogenesis. Genotype
alone therefore accounts for a signiﬁcant but limited proportion
of CD risk and biomarkers of non-genetic inﬂuences must be
sought.11 12 Studying siblings of patients with CD may provide
insights into genetic and non-genetic factors relevant to CD
pathogenesis, that are more readily apparent in the absence of
established disease.
Several authors have sought to describe the phenotype of the
‘at-risk’ relatives of patients with CD. FC is increased in up to
49% of ﬁrst-degree relatives,13 and IP is reportedly increased in
CD relatives, although data are inconsistent.8 14–16 Fewer data
describe the intestinal microbiota of healthy relatives of patients
with CD; one study reported speciﬁc relative-associated dysbiosis
distinct from that associated with CD,17 while other data have sug-
gested an association between dysbiosis in relatives with CD and
CD-associated alleles.18 However, the microbial characteristics of
relatives’ dysbiosis are inconsistent between studies.
Interaction between gut microbiota and the mucosal immune
system is a cornerstone of CD pathogenesis, yet few data exist
that deﬁne the immune phenotype of those at risk of CD.19
Defects in oral tolerance induction have been reported in some
ﬁrst-degree relatives of patients with CD20 but there has been
no detailed analysis of the associated T cell phenotype and
function.
Limitations of previous studies include recruitment of
unaffected parents of patients with CD, and the determination
of speciﬁc aspects of the at-risk phenotype in isolation. The
inclusion of siblings is preferable to parents because relevant
risk factors such as raised FC21 and altered gut microbiota,22
may vary with age. Furthermore, parents are usually beyond the
peak age of CD incidence, reducing the power to detect biomar-
kers of IBD susceptibility. Finally, comparison of individuals
separated by a generation may be confounded by changes in
prevailing environmental conditions. These issues are circum-
vented in the current study by comparing phenotypes of
patients and their unaffected siblings.
The current study was designed to test the hypothesis that
unaffected siblings of patients with CD share features of a ‘CD
phenotype’ that may afford insights into disease pathogenesis
and provide markers of CD risk. This study is unique by deﬁn-
ing multiple dimensions of the CD phenotype simultaneously,
including microbial and immunological markers alongside FC,
IP and genotype. This has allowed interrogation of the relative
impact and interactions of these features.
MATERIALS AND METHODS
Patients with inactive CD (Crohn’s Disease Activity Index
(CDAI) <150 and C reactive protein (CRP) <5 mg/L) and their
healthy siblings (both aged 16–35 years) were recruited from
clinics at Barts and London, and University College Hospitals
NHS Trusts, UK between June 2008 and December 2011.
Healthy controls were recruited by circular email sent to staff
and students at King’s College London during the same period.
Patients required a conﬁrmed diagnosis of CD for >3 months
and an available sibling. For exclusion criteria see online
supplementary table S1. All participants provided written
informed consent. Ethical approval was provided by Bromley
Local Research Ethics Committee (reference 07/H0805/46).
At screening, demographics, medical and drug exposure
history, physical examination, CRP, inclusion and exclusion cri-
teria were assessed. Written instructions regarding avoidance of
prebiotics/probiotics for 4 weeks, non-steroidal anti-
inﬂammatory drugs for 1 week and alcohol for 24 h before the
study were provided. Blood samples were taken for routine
haematology/biochemistry, T cell analysis and genotyping.
Participants completed the 5-h urine collection for IP and
underwent ﬂexible rectoscopy without bowel cleansing. Biopsies
from non-inﬂamed rectum were sent for routine histological
analysis. Stool was obtained for and stored at −20°C before pro-
cessing for FC quantiﬁcation and microbiological analysis.
Laboratory methods
Fecal calprotectin
Faecal samples were transferred on ice before FC extraction and
ELISA analysis (Calpro AS, Lysaker, Norway) according to the
manufacturer’s instructions using duplicate appropriately
diluted samples. FC concentration was determined relative to
standard curves and expressed as mg/g of faeces.
Gut microbiota
Gut microbiota that comprise the reported dysbiosis of CD
were analysed using quantitative PCR (qPCR). Faecal DNA
extraction was carried out using the FastDNA spin kit for soil
and the FastPrep-24 bead homogeniser (MP Biomedicals, Solon,
Ohio, USA) following the manufacturer’s instructions. A SYBR
Green qPCR analysis of faecal DNA was performed as described
previously23 with the following modiﬁcations: ampliﬁed bacter-
ial 16S rRNA genes served as standard templates as previously
described except for Ruminococcus bromii L2–6324 for the
Ruminococcus primers; for E coli primers, E coli XL1-Blue was
used. PCR reactions were performed in quadruplicate using a
7900HT Fast Real-Time PCR machine (Life Technologies). Data
were analysed with SDS V.2.4 software (Life Technologies).
Faecal water content was measured by lyophilisation and con-
centrations of bacteria expressed as log10 copies/gram dry
faeces. Normalised proportions of bacteria were obtained by
dividing speciﬁc group quantities through universal quantities.
For details of primers and PCR conditions see online
supplementary table S2.
Peripheral blood T cell ﬂow cytometry
Whole blood, collected in lithium-heparin Vacutainer tubes (BD
Bioscience), was stored at room temperature for ≤4 h before
labelling with ﬂuorescently conjugated monoclonal antibodies to
detect CD3 T cells, naïve (CD45RA+) and memory (CD45RA−)
subsets of CD4 and CD8 T cells. Integrin α4β7 expression was
assessed by labelling with anti-β7 (see online supplementary
methods for antibodies used).
Data were acquired using a LSRII 4-colour ﬂow cytometer
(BD Bioscience) and collected using ﬂuorescence-activated cell
sorting Diva software V.4.1.2 (BD Bioscience) using Flow-Count
ﬂuorospheres (Beckman Coulter) for absolute quantitation.
Colour compensation was performed ofﬂine using Winlist V.6.0
(Verity Software House).
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Genotyping
Human DNA was extracted from whole blood using the phenol
chloroform-isoamyl alcohol method.25 Genotyping was performed
using the Illumina Inﬁnium Immunochip,26 which includes 70 of
the 71 CD disease risk loci described in Franke et al.19 To increase
detection of NOD2 mutations and capture the enhanced risk of
NOD2 compound heterozygosity, three NOD2 (rs2066845/
G908R, rs2066844/R702W and rs5743293/3020insC) were indi-
vidually assessed. Cumulative genotype relative risk (GRR) for each
participant was therefore calculated across a total of 72 CD risk
loci. A population distribution model of CD risk was generated
using the REGENT R program27 and previously published ORs.19
Participants were categorised into reduced, average, elevated or
high genotypical risk with reference to this model.28
Intestinal permeability
IP tests were carried out using lactulose-rhamnose tests.29 After
overnight fasting, participants consumed 450 mL water contain-
ing 5 g lactulose, 2 g mannitol and 1 g L-rhamnose (BCM
Specials, Nottingham, UK), followed by a 5 h urine collection.
Aliquots from the pooled urine sample were stored at −20°C
until analysis.
Urinary sugar separation and detection was carried out by
liquid chromatography-tandem mass spectrometry. Following
microcentrifugation, supernatant was transferred to a LC-2000
platform autosampler ( Jasco, Easton, Maryland, USA), and
urinary sugars separated by high performance liquid chromatog-
raphy using an amino column in hydrophilic interaction liquid
chromatography mode. Sugars were quantiﬁed by electrospray
tandem mass spectrometry, using the API 3200 (AB Sciex,
Framingham, Massachusetts, USA).
Power calculation
The hypothesis was that siblings would demonstrate multiple
aspects of a CD phenotype distinct from healthy controls. In
order to calculate the number of participants required, we per-
formed a power calculation based upon detecting lower concen-
trations of F prausnitzii in siblings compared with healthy
controls. This determined that 21 subjects would be required in
each group to detect a difference in F prausnitzii of 0.3 log10
between siblings and healthy controls assuming a SD of 0.3
log10 (power 0.9, signiﬁcance level 0.05).
Statistical analysis
Normality was determined by visual assessment of histograms
and Shapiro-Wilk test. Parametric analyses (one-way analysis of
variance or Student’s t test) and non-parametric analyses
(Mann-Whitney or Kruskal-Wallis tests) with Tukey’s or
Bonferroni post hoc corrections applied as appropriate.
Correlations between continuous variables were assessed with
Pearson’s correlation coefﬁcients (PCCs). Associations between
categorical variables were assessed using χ2 tests. Hierarchical
multiple regression analysis determined dependence between
variables, after controlling for the effect of other factors. The
capacity of combined variables to discriminate between the
three groups was determined using discriminant analysis (SPSS,
version 18.0).
RESULTS
Participants and genotype relative risk
Twenty-two patients with CD in remission (mean CDAI 71
(SD 44.8)), 21 of their healthy siblings and 25 controls matched
by group for age, gender, body mass index, ethnicity, smoking
status and median number of siblings were recruited (see online
supplementary table S3). Patients’ disease characteristics were
representative of northern European populations. All partici-
pants had normal CRP (<5 mg/L) at screening. Nine (41%)
patients and four (19%) siblings carried at least one NOD2
mutation compared with four (16%) controls (p=0.054). No
participant had evidence of either macroscopic or microscopic
mucosal inﬂammation. Predictably, higher proportions of
patients and siblings had an elevated or high GRR across the 72
CD risk loci assessed, compared with controls (table 1).
Faecal calprotectin was increased in patients and siblings
FC was signiﬁcantly higher in patients (252 mg/g, IQR 125–
775 mg/g) compared with siblings (36 mg/g, IQR 17–65 mg/g,
p<0.003) and controls (17 mg/g, IQR 9–41 mg/g, p<0.003). The
proportion with FC concentrations above normal (50 mg/g), was
greater in patients (21, 95%) versus controls (2, 8%, p<0.001),
and siblings (8, 38%) versus controls, (p=0.028). FC was not
affected by smoking status or disease location and did not correlate
between related sibling-patient pairs (PCC=−0.005, p=0.983).
Intestinal permeability was increased in patients
but not siblings
Signiﬁcantly more patients (12, 57%) had abnormal IP (ratio of
urinary lactulose to rhamnose >0.05) than siblings or controls
(6, (29%) and 5 (23%), respectively, p=0.044), but IP was not
signiﬁcantly different between siblings and controls. IP did not
correlate between sibling pairs, (PCC −0.024, p=0.917), but
signiﬁcantly correlated with FC across all groups (PCC 0.283,
p=0.023).
A Crohn’s-like dysbiosis, including reduced F prausnitzii, was
observed in siblings
Compared with controls, patients had signiﬁcantly lower con-
centrations of total bacteria, F prausnitzii, Clostridia cluster IV,
Ruminococcus spp., Roseburia spp., Bacteroides-Prevotella and
Biﬁdobacterium adolescentis; a dysbiosis comparable with that
previously described in CD.3 Strikingly, siblings also had signiﬁ-
cantly lower concentrations of F prausnitzii, Clostridia cluster
Table 1 The number of patients’ siblings and controls observed in each of the four genotype relative risk (GRR) categories
GRR categories, n (%) Patients (n=22) Siblings (n=21) Controls (n=25) p Values
High (GRR >4.185) 3 (14) 1 (5) 0 (0) Pat-con 0.045
Sib-con 0.046
Pat-sib 0.726
Elevated (GRR 2.273–4.185) 2 (9) 3 (14) 0 (0)
Average (GRR 0.445–2.277) 11 (50) 12 (57) 11 (44)
Reduced (GRR <0.445) 6 (27) 5 (24) 14 (56)
Categorised GRR in patients with CD and siblings was significantly greater compared with controls. Genotyping was performed using the Illumina Infinium Immunochip as described in
the methods.
CD, Crohn’s disease.
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IV and Roseburia spp. compared with controls. However, con-
centrations of total bacteria, Bacteroides-Prevotella and B adoles-
centis were not different between siblings and controls (table 2).
The microbiota was also analysed as relative proportions of each
group. A similar dysbiosis was described in the patients (see
online supplementary table S4), with an additional ﬁnding that
proportions of E coli were increased in patients (0.12% SD
3.95%) compared with controls (0.02% SD 0.10%, p=0.027)
but were similar between siblings (0.05% SD 0.14%) and con-
trols (p=0.825).
Proportions of F prausnitzii were signiﬁcantly correlated
between sibling pairs (PCC 0.436, p=0.043) as were Clostridia
cluster IV (PCC 0.532, p=0.011) and concentrations of Clostridia
cluster XIVa (PCC 0.543, p=0.009). Smoking and immunosup-
pressant use were not associated with dysbiosis. Likewise, IP and
FC were not independently associated with dysbiosis (data not
shown). In addition to the effect of group in predicting the con-
centration of Bacteroides-Prevotella, (R2=0.276, F1,66=25.221,
p<0.001), there was a signiﬁcant association between elevated/
high GRR and concentrations of Bacteroides-Prevotella
(R2=0.327, R2 change=0.050, F1,66=4.838, p=0.031), with
grouping accounting for 28% and GRR for 5% of the variation.
Concentrations and proportions of other bacteria did not vary
according to GRR.
Memory T cells were increased in patients and their siblings
The proportion of blood T cells that were CD45RA− memory
T cells was signiﬁcantly higher in patients and siblings compared
with controls, ﬁgure 1A. The higher proportion of memory Tcells
observed in patients and siblings compared with controls was
signiﬁcant in the CD4 T cell subset (65%, SD 13%; 69%, SD
12%; 55%, SD 13%, respectively; p=0.001), and a trend towards
higher proportions of memory cells was also seen in CD8 T cells
(53%, SD 19%; 57%, SD 17%; 45%, SD 15%, respectively;
p=0.054). Total frequencies of peripheral CD3 Tcells were signiﬁ-
cantly lower in patients compared with siblings or controls, online
supplementary ﬁgure S1. This observation complements previous
data indicating that blood T cell numbers are reduced in active
CD.30 Absolute quantitation of T cell subsets revealed that the
higher proportion of memory T cells was attributable to lower
concentrations of CD45RA naïve T cells in patients and siblings
compared with controls, whereas memory T cell frequencies did
not differ signiﬁcantly compared with controls, ﬁgure 1B–E.
Naïve CD4 T cells exhibit enhanced gut-homing potential
in patients and siblings
The relative proportion of β7+ and β7− cells in each T cell
subset was analysed individually: proportions of CD4 naïve
CD45RA+ T cells expressing β7 was signiﬁcantly higher in
patients and siblings compared with controls, ﬁgure 2A–D.
Proportions of T cells expressing β7 did not signiﬁcantly differ
between groups for any of the other T cell subsets. The propor-
tion of memory T cells expressing β7 (PCC 0.564, p=0.006),
but not the proportion of β7+ CD4 naïve T cells , was signiﬁ-
cantly correlated between patient-sibling pairs.
Correlation between factors in healthy siblings
As demonstrated in the whole cohort, there was a negative correl-
ation between the concentration of Bacteroides-Prevotella and
GRR in siblings (PCC=−0.505, p=0.019). Thus siblings with the
Table 2 Concentrations of bacterial groups and species in faecal samples were significantly different between patients, siblings and controls
Concentrations of bacteria, log10 copies/g median (IQR)
p Value Between-group comparisons p ValuesPatients (n=22) Siblings (n=21) Controls (n=25)
Faecalibacterium prausnitzii 6.88 (5.03–9.35) 9.27 (8.12–9.78) 9.59 (9.34–10.14) <0.001 Pat-Sib: 0.006
Pat-Con: <0.003*
Sib-Con: 0.048
Clostridia cluster IV 7.76 (6.54–9.56) 9.34 (8.76–9.93) 9.69 (9.48–10.26) <0.001 Pat-Sib: 0.045
Pat-Con: <0.003
Sib-Con: 0.030
Clostridia cluster XIVa 9.86 (9.07–10.31) 10.13 (9.64–10.46) 10.19 (9.85–10.85) 0.099 –
Cluster IV Ruminococcus spp. 7.05 (5.94–8.29) 8.75 (8.04–9.33) 9.55 (8.37–10.02) <0.001 Pat-Sib: <0.003
Pat-Con: <0.003
Sib-Con: 0.084
Roseburia spp. 9.19 (7.35–9.85) 9.34 (7.21–9.70) 9.92 (9.39–10.15) 0.004 Pat-Sib: 1.000
Pat-Con: 0.027
Sib-Con: 0.009
Bacteroides-Prevotella 8.83 (8.35–10.05) 10.16 (9.50–10.70) 10.48 (10.08–10.80) <0.001 Pat-Sib: 0.009
Pat-Con: <0.003
Sib-Con: 0.639
Escherichia coli 7.95 (6.61–9.00) 7.15 (6.95–8.07) 7.32 (6.79–8.00) 0.553 –
Bifidobacterium 9.36 (8.24–10.00) 9.84 (9.41–10.05) 9.98 (9.32–10.16) 0.154 –
Bifidobacterium longum 8.91 (6.80–9.50) 9.13 (8.67–9.56) 9.24 (8.18–9.61) 0.640 –
Bifidobacterium adolescentis 5.76 (4.69–8.78) 8.87 (5.50–9.30) 9.20 (7.88–9.56) 0.018 Pat-Sib: 0.228
Pat-Con: 0.021
Sib-Con: 0.714
Universal 10.68 (10.16–10.89) 10.84 (10.55–11.03) 10.97 (10.76–11.29) 0.010 Pat-Sib: 0.759
Pat-Con: 0.015
Sib-Con: 0.117
The CD dysbiosis broadly reflected that previously described: reduced Firmicutes (including F prausnitzii and Clostridia cluster IV), Bacteroides-Prevotella, B adolescentis and total
bacteria. Similar reductions in Firmicutes species including F prausnitzii and Clostridia cluster IV also characterised the sibling dysbiosis, whereas concentrations of
Bacteroides-Prevotella, B adolescentis and the overall concentration of bacteria were similar between siblings and controls. Bacterial DNA was extracted from faecal samples and
detected using quantitative PCR probes as detailed in the methods and online supplementary methods.
*Due to Bonferroni correction of p values, a minimum value of <0.003 is reported rather than <0.001.
CD, Crohn’s disease.
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highest genetic risk of CD shared aspects of the CD associated dys-
biosis with their affected relative. In addition, there was a negative
correlation between the concentration of Clostridia cluster IV and
IP (PCC=−0.514, p=0.017), the concentration of blood CD4
naïve T cells (PCC=−0.521, p=0.016) and the proportion of
CD4 naïve T cells which expressed β7 integrin (PCC=−0.475,
p=0.030). However, there was no correlation between Clostridia
cluster IV and FC. Thus, reduced concentrations of Clostridia
cluster IV in siblings were associated with several phenotypical
characteristics that are associated with CD. Interestingly these cor-
relations were not present in patients with established disease or
healthy controls, which would support a role for this aspect of the
dysbiosis in the pathogenesis of disease.
The multidimensional phenotype discriminates between
patients, siblings and healthy controls
We next performed a discriminant analysis to determine whether
combining genetic risk, FC, IP, gut microbiota and immunological
parameters could distinguish between patients, ‘at-risk’ siblings and
healthy controls, ﬁgure 3. Independent variables were entered into
the model and two discriminant functions (linear combinations of
the variables, whose values are as close as possible within groups and
as far apart as possible between groups) were calculated, with a com-
bined χ2=80.409, degrees of freedom (df)=20, p<0.001. The two
discriminant functions accounted for 87% and 13% of the
between-group variance, respectively. Function 1 maximally separated
patients from controls. Function 2 maximally separated siblings from
controls, and after removal of function 1, the discriminating power
of function 2 remained signiﬁcant: χ2=15.569, (df=9), p=0.049.
The loading matrix of correlations between predictor variables and
discriminant functions suggested that variables contributing signiﬁ-
cantly to function 1 (providing maximal discrimination between
patients and controls) were predominantly microbiological: concen-
trations of F prausnitzii, Ruminococcus spp., Bacteroides-Prevotella
and Clostridia cluster IV, in addition to FC, (table 3). In contrast, the
variables contributing signiﬁcantly to function 2 (providing maximal
discrimination between siblings and controls) were T cell attributes
including the proportion of CD4 T cells expressing β7 integrin and
the proportion of T cells with a memory cell phenotype, as well as
concentrations of Roseburia spp.
DISCUSSION
This is the ﬁrst study to provide detailed and simultaneous ana-
lysis of the faecal microbiology, IP, FC and blood T cell pheno-
type of a cohort of clinically and genetically well-characterised
patients with quiescent CD. Uniquely, the equivalent detailed
assessments were also performed in healthy siblings of the
patients with CD and matched unrelated controls. We report
Figure 1 (A) Proportions of peripheral blood T cells with a memory (CD45RA-) phenotype were signiﬁcantly greater in patients (n=22) and siblings
(n=21) compared with healthy controls (n=25). (B–E) The predominance of the memory phenotype was attributable to a relative lack of naïve T
cells. Although concentrations of T cells in patients were contributed to by the use of immunosuppressants by half of patients, concentrations of
naïve T cells were also reduced in immunosuppressant naïve siblings, and in the CD4 naïve T cell population this difference was signiﬁcant. Whole
blood was labelled with ﬂuorescently conjugated monoclonal antibodies before acquisition of data using a LSRII ﬂow cytometer.
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that siblings of patients with CD share multiple features of the
CD phenotype in addition to genotype-related risk (table 4),
including reduced Firmicutes such as F prausnitzii, predomin-
ance of the memory phenotype in blood T cells, and elevated
FC. We hypothesise that the unaffected sibling phenotype pro-
vides a unique window into factors important in CD pathogen-
esis. Studying healthy, ‘at-risk’ siblings allows the description of
pathogenic factors in the absence of the inﬂuence of disease,
surgery and pharmacotherapy that may distort the phenotype in
patients. Finally, this study provides proof of principle that
multidimensional phenotyping can be used to discriminate a
population of healthy at-risk individuals from background risk
controls.
Genotype relative risk
The patient and sibling cohorts were enriched for genetic loci
associated with CD. The genetic validity of the cohort is
Figure 2 (A–D) Signiﬁcantly higher
proportions of CD4 naïve T cells
expressed β7 integrin in patients
(n=22) and siblings (n=21) compared
with controls, (n=25). Relative
abundances of β7+ cells did not differ
between groups for the other T cell
subsets. Whole blood was labelled
with ﬂuorescently conjugated
monoclonal antibodies before
acquisition of data using a LSRII ﬂow
cytometer.
Figure 3 Direct discriminant function analysis revealed that the
variables contributing signiﬁcantly to function 1 (which provided
maximal separation of patients with Crohn’s disease from controls)
were: elevated faecal calprotectin and altered faecal microbiota
(reduced Faecalibacterium prausnitzii, cluster IV Ruminococcus spp.,
Bacteroides-Prevotella and Clostridia cluster IV). In contrast the
variables contributing signiﬁcantly to function 2 (which provided
maximal discrimination of siblings from controls) were: increased β7
integrin expression by circulating naïve CD4 T cells, an increased
proportion of memory CD4 T cells and reduced faecal Roseburia spp.
Table 3 Loading matrix of correlations between predictor
variables and the two discriminant functions (figure 3) where
function 1 provided most discrimination between patients and
controls and function 2 provided maximal discrimination between
siblings and controls
Pooled within-groups
correlations between
variables and discriminant
functions
Function 1 Function 2
Faecalibacterium prausnitzii, (log10/g) −0.608* 0.050
Ruminococcus spp., (log10/g) −0.544* 0.043
Faecal calprotectin, (mg/g) 0.528* −0.283
Bacteroides-Prevotella, (log10/g) −0.473* 0.037
Clostridia cluster IV, (log10/g) −0.359* −0.163
Genotype relative risk 0.251 0.043
Proportion of CD4+ naïve cells expressing β7
integrin, (%)
0.226 0.596*
Roseburia spp., (log10/g) −0.234 −0.466*
Proportion of memory T cells, (%) 0.196 0.439*
The contribution of each aspect of the multidimensional phenotype to each function
is reflected by the pooled within-groups correlations between variables and
discriminant functions. The values refer to the strength of the correlation of variables
with each discriminant function; the positive/negative symbol refers to the direction of
the correlation.
*Factors with a discriminant loading >0.300 are considered to contribute significantly
to the discriminant function.
CD, Crohn’s disease.
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supported by higher genetic risk in siblings, a NOD2 mutation
rate (patients=41%, controls=16%) similar to previous data31
and the ratio of siblings to patients carrying any NOD2 muta-
tion. However, the amount of total disease variance that can be
attributed to current genetic ﬁndings in CD is still low
(<15%),1 hence genotyping alone is inadequate to accurately
identify at-risk individuals12 and further research is required to
identify features associated with predisposition towards CD.
Combining such information with data on genotype may be a
powerful method to detect risk.
Fecal calprotectin and intestinal permeability
Elevated FC and IP are associated with established CD, but only
elevated FC appears to contribute to the sibling ‘at-risk’ pheno-
type in this study.13 This would suggest that breach of the intes-
tinal barrier is not an early event in CD pathogenesis. Some
data suggest that increased IP may only be apparent in relatives
when exposed to triggers such as aspirin ingestion,15 and thus
may not have been detected in the current study. The lack of
correlation in FC between sibling pairs may imply that raised
FC is not driven by genetic or early environmental factors
shared between siblings.
Dysbiosis
Consistent with previous reports,3 the CD dysbiosis in our study
included reduced F prausnitzii, Clostridia cluster IV and
Bacteroides-Prevotella. However, whether this dysbiosis predis-
poses towards CD or is an outcome of established disease
cannot be determined by studying patients in isolation.
Strikingly, siblings share elements of the CD dysbiosis, speciﬁc-
ally depletion of the Firmicutes F prausnitzii and Clostridia
cluster IV, suggesting that these elements of CD dysbiosis are
not purely consequent to established disease. The focus of the
sibling dysbiosis on diminished Firmicutes populations is note-
worthy given the range of mechanisms by which Firmicutes con-
tribute to gut health32 and that phylum member F prausnitzii
predicts CD natural history.2 In contrast, the reduction in
Bacteroides-Prevotella and B adolescentis and increased E coli
seen in patients with CD were not found in their siblings, sug-
gesting that these may become disturbed once disease is estab-
lished. This study focused on aspects of the CD dysbiosis that
have been reported previously and therefore used qPCR.
Alternative methods such as 16S pyrosequencing might detect
unsuspected alterations in the microbiota in siblings that had
not been reported as part of the dysbiosis in CD.
Few previous studies deﬁned the gut microbiota of relatives of
patients with CD with reference to healthy controls. One sug-
gested that the organisms comprising the dysbiosis varied
between patients with CD and their relatives.17 These ﬁndings
are at odds with our study, where the sibling dysbiosis was
similar to that in patients. This disparity may relate to previous
studies including more heterogeneous groups of relatives. In
contrast, the current study recruited only true siblings, poten-
tially increasing the relevance of the dysbiosis we describe to
early events in CD pathogenesis. Data from the current study
suggest that loss of butyrate producers is common to patients
with CD and their siblings, and is potentially the earliest micro-
biological step towards CD. Butyrate has recently been sug-
gested to regulate the size of the colonic regulatory T cell pool
and protect against murine colitis.33
In health, the intestinal microbiota is more similar between
related than unrelated individuals.34 However, this similarity is
reduced where one relative has CD.35 Therefore, it would be
predicted that siblings in the current study, discordant for
disease phenotype, would have dissimilar microbiota. This was
seen with Bacteroides-Prevotella, B adolescentis and E coli, but
intersibling similarity was preserved for three bacterial groups
within the Firmicutes phylum, suggesting this aspect of the CD
dysbiosis is either genetically programmed, or that an early
environmental exposure has a persistent impact on the micro-
biota, regardless of the later development of CD. The lack of
association between GRR and Firmicutes abundance in the
current study may favour prenatal, childhood or adolescent
environmental factors in conferring this phenotype. Embryo
transfer models demonstrate a maternal effect to determine the
microbiota independent of genetic inﬂuence.36 Candidate
maternally derived environmental factors include delivery by
caesarean section and a protective effect of breastfeeding.37
However, a genetic inﬂuence over a CD-speciﬁc aspect of the
dysbiosis was suggested by the association between GRR and
Bacteroides-Prevotella. It may be speculated that the develop-
ment of CD may require multiple microbiological ‘hits’, includ-
ing environmentally acquired dysbiosis (to which siblings are
also exposed), as well as genetically driven dysbiosis (more
prominent in patients in this study).
T cell phenotype
We demonstrate that memory T cell phenotype predominance,
previously described in active CD5 is also present in inactive
CD, particularly among CD4 T cells. However, in contrast to
the redistribution of T cells from naïve to memory
Table 4 Summary of the phenotype of patients with CD and their healthy siblings as compared with unrelated healthy controls
Patients with CD Unaffected siblings
Genotype relative risk ↑ ↑
Faecal calprotectin ↑↑ ↑
Intestinal permeability ↑ ↔
Gut microbiota
↓ Faecalibacterium prausnitzii/Firmicutes*
↓ Bacteroides-Prevotella
↓ Bifidobacterium adolescentis
↑ Escherichia coli
↓ F prausnitzii/Firmicutes*
Blood
T cells
↑ memory phenotype associated with naïve CD4 T cell
lymphopenia
↑ expression of β7 integrin by naïve CD4 T cells
↑ memory phenotype associated with naïve CD4 T cell
lymphopenia
↑ expression of β7 integrin by naïve CD4 T cells
Novel observations from this study are highlighted in bold.
*Firmicutes which were reduced were: F prausnitzii, Clostridia cluster IV, Roseburia spp., and in patients also Ruminococcus spp.
CD, Crohn’s disease.
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compartments previously reported in active CD,5 we show that
in inactive CD blood naïve T cell frequencies are depleted in iso-
lation. In patients with CD, depletion of blood naïve CD4 T
cells may therefore be a marker of disease that is independent of
inﬂammation and may precede CD onset. Strikingly, a naïve
CD4 T cell lymphopenia was demonstrated for the ﬁrst time in
unaffected siblings of patients with CD. It is unknown whether
this naïve T cell lymphopenia reﬂects reduced generation of
naïve T cells, their sequestration outside the circulation or redis-
tribution towards a memory population which has limited per-
sistence in the circulation. It is tempting to speculate that
peripheral homoeostasis of naïve T cells, which is driven by low-
afﬁnity T cell receptor stimulation and interleukin 7 signalling
(and may depend on the presence of the intestinal micro-
biota38), may be disrupted in patients with CD and their sib-
lings. It is noteworthy that depletion of naïve CD4 T cells was
associated with increased expression of β7 integrin, a marker of
gut tropism. In lymphocyte-replete animals, expression of the
integrin α4β7 on naïve T cells facilitates their entry into
gut-associated lymphoid tissue.39 40 However, under lymphope-
nic conditions, IL-7 is induced which enhances α4β7 expression
by naïve T cells and results in their migration into the intestinal
mucosa.41 Therefore, perturbed homoeostasis of naïve CD4 T
cells may be indicative of altered trafﬁcking through organised
lymphoid tissue and/or the intestinal mucosa in patients with
CD and those at risk of CD.
Interactions between dimensions of the CD phenotype
A unique feature of the current study is the simultaneous meas-
urement of a variety of dimensions of the CD phenotype that
permits interrogation of relationships between factors within and
between groups. Thus the dysbiosis in siblings was associated
with phenotypical features associated with CD (increased perme-
ability, the concentration of blood CD4 naïve Tcells and the pro-
portion of CD4 naïve T cells which expressed β7 integrin).
Whereas, dysbiosis did not correlate with FC in either patients or
siblings, indicating that it occurs independently of intestinal
inﬂammation. The proportion of memory T cells correlated
between patient-sibling pairs, but the lack of association between
GRR and the proportion of memory T cells (and other features)
may imply limited genetic determination. Consonant with this, a
recent reanalysis of an early twin cohort estimated CD concord-
ance in monozygotic twins to be 27% rather than the previously
reported 58%.42 43 However, the contribution of genotype to
CD pathogenesis will be better described as technological
advances facilitate the measurement of ‘non-code’ genetic effects
such as epistatic, epigenetic or parent-of-origin effects.
Finally, in addition to detecting correlations between individ-
ual factors, our study has allowed a multidimensional compari-
son of the CD, sibling and healthy control phenotypes, enabling
the identiﬁcation of factors that discriminate healthy siblings of
patients with CD from healthy controls. Microbiological factors
such as F prausnitzii and Bacteroides-Prevotella contributed
more to discrimination of patients from healthy controls but
were less signiﬁcant in discrimination of the sibling phenotype,
which was more dependent on immunological factors. Whether
this sibling immune-characterised phenotype precedes CD onset
or is an alternative phenotype of individuals who do not possess
sufﬁcient cumulative microbial or other triggers required to
develop CD, may only be established with longitudinal studies.
Future studies investigating CD risk should simultaneously
assess multiple dimensions. The CD and at-risk phenotypes
described herein must be conﬁrmed in other populations. In
view of the breadth of measures reported in this study, we
cannot exclude a type II error in some circumstances. In add-
ition, newly uncovered features of the at-risk phenotype
reported in this study such as the importance of F prausnitzii,
naïve CD4 T cell lymphopenia and altered expression of
gut-homing markers provide fresh avenues of investigation into
CD risk and pathogenesis. For example, the mechanisms of
CD4 T cell lymphopenia in CD and ‘at-risk’ siblings remain to
be determined, and the signiﬁcance of potential pathogenic
mechanisms such as Firmicutes short-chain fatty acid produc-
tion, must be tested. Longitudinal studies are required to deter-
mine the capacity of the multidimensional analysis outlined in
this study to predict disease in at-risk groups. Such longitudinal
studies will be challenging, although it may be possible to
perform repeated measurements at intervals in the offspring of
patients with CD. This would have signiﬁcant potential beneﬁts
to patients and their families as well as building on the insights
into disease pathogenesis provided in this study.
Contributors CRH: study concept and design; recruitment of participants and
acquisition of data; analysis and interpretation of data; drafting of the manuscript;
critical revision of the manuscript for important intellectual content; statistical
analysis; obtained funding. NEM: assistance with analysis and interpretation of
immunology data; critical revision of the manuscript for important intellectual
content. PL and FMF: assistance with analysis and interpretation of microbiology
data; critical revision of the manuscript for important intellectual content; technical
support. SM: assistance with recruitment of participants; critical revision of the
manuscript for important intellectual content. KT: Human DNA extraction; assistance
with analysis and interpretation of genetics data; critical revision of the manuscript
for important intellectual content. NJP: assistance with analysis and interpretation of
genetics data; critical revision of the manuscript for important intellectual content.
TM: statistical advice, interpretation of statistical ﬁndings; critical revision of the
manuscript for important intellectual content. AJS, KW and JOL: study concept and
design; analysis and interpretation of data; critical revision of the manuscript for
important intellectual content; obtained funding, study supervision.
Funding This research was funded by the charity Core.
Competing interests CRH was supported by a clinical research fellowship granted
by the charity Core. FMF and PL received ﬁnancial support from the Scottish
Government Rural and Environmental Sciences and Analytical Services. NJP and KT
were supported by the National Institute for Health Research (NIHR) Biomedical
Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust and King’s
College London.
Ethics approval Bromley Local Research Ethics Committee (reference 07/H0805/46).
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Additional data are included in the online
supplementary methods section for online publication.
REFERENCES
1 Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the
genetic architecture of inﬂammatory bowel disease. Nature 2012;491:119–24.
2 Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an
anti-inﬂammatory commensal bacterium identiﬁed by gut microbiota analysis of
Crohn disease patients. Proc Natl Acad Sci USA 2008;105:16731–6.
3 Sartor RB. Microbial inﬂuences in inﬂammatory bowel diseases. Gastroenterology
2008;134:577–94.
4 Strober W, Fuss IJ. Proinﬂammatory cytokines in the pathogenesis of inﬂammatory
bowel diseases. Gastroenterology 2011;140:1756–67.
5 Hart AL, Kamm MA, Knight SC, et al. Quantitative and functional characteristics of
intestinal-homing memory T cells: analysis of Crohn’s disease patients and healthy
controls. Clin Exp Immunol 2004;135:137–45.
6 Garcia de TJ, Manzano L, Leal JC, et al. Active Crohn’s disease patients show a
distinctive expansion of circulating memory CD4+CD45RO+CD28null T cells. J Clin
Immunol 2004;24:185–96.
7 Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal
inﬂammation are predictive of relapse in patients with inﬂammatory bowel disease.
Gastroenterology 2000;119:15–22.
8 Buhner S, Buning C, Genschel J, et al. Genetic basis for increased intestinal
permeability in families with Crohn’s disease: role of CARD15 3020insC mutation?
Gut 2006;55:342–7.
9 Meuwis MA, Vernier-Massouille G, Grimaud JC, et al. Serum calprotectin as a
biomarker for Crohn’s disease. J Crohns Colitis 2013;7:e678–83.
Hedin CR, et al. Gut 2014;63:1578–1586. doi:10.1136/gutjnl-2013-306226 1585
Inﬂammatory bowel disease
 group.bmj.com on October 6, 2014 - Published by gut.bmj.comDownloaded from 
10 Calkins BM, Mendeloff AI. Epidemiology of inﬂammatory bowel disease. Epidemiol
Rev 1986;8:60–91.
11 Hedin CR, Stagg AJ, Whelan K, et al. Family studies in Crohn’s disease: new
horizons in understanding disease pathogenesis, risk and prevention. Gut
2012;61:311–18.
12 Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex
diseases. Nature 2009;461:747–53.
13 Thjodleifsson B, Sigthorsson G, Cariglia N, et al. Subclinical intestinal inﬂammation:
an inherited abnormality in Crohn’s disease relatives? Gastroenterology
2003;124:1728–37.
14 Munkholm P, Langholz E, Hollander D, et al. Intestinal permeability in patients with
Crohn’s disease and ulcerative colitis and their ﬁrst degree relatives. Gut 1994;35:68–72.
15 Soderholm JD, Olaison G, Lindberg E, et al. Different intestinal permeability patterns
in relatives and spouses of patients with Crohn’s disease: an inherited defect in
mucosal defence? Gut 1999;44:96–100.
16 May GR, Sutherland LR, Meddings JB. Is small intestinal permeability really
increased in relatives of patients with Crohn’s disease? Gastroenterology
1993;104:1627–32.
17 Joossens M, Huys G, Cnockaert M, et al. Dysbiosis of the faecal microbiota in
patients with Crohn’s disease and their unaffected relatives. Gut 2011;60:631–7.
18 Turpin W, Moreno-Hagelsieb G, Silverberg MS, et al. Speciﬁc Crohn’s Disease (CD)
associated risk alleles are associated with the composition of the intestinal
microbiota in healthy First Degree Relatives (FDR) of CD subjects. Gastroenterology
2013;142:S57.
19 Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the
number of conﬁrmed Crohn’s disease susceptibility loci. Nat Genet 2010;42:1118–25.
20 Kraus TA, Cheifetz A, Toy L, et al. Evidence for a genetic defect in oral tolerance
induction in inﬂammatory bowel disease. Inﬂamm Bowel Dis 2006;12:82–8.
21 Joshi S, Lewis SJ, Creanor S, et al. Age-related faecal calprotectin, lactoferrin and
tumour M2-PK concentrations in healthy volunteers. Ann Clin Biochem
2010;47:259–63.
22 Woodmansey EJ, McMurdo ME, Macfarlane GT, et al. Comparison of compositions
and metabolic activities of fecal microbiotas in young adults and in
antibiotic-treated and non-antibiotic-treated elderly subjects. Appl Environ Microbiol
2004;70:6113–22.
23 Ramirez-Farias C, Slezak K, Fuller Z, et al. Effect of inulin on the human gut
microbiota: stimulation of Biﬁdobacterium adolescentis and Faecalibacterium
prausnitzii. Br J Nutr 2009;101:541–50.
24 Dabek M, McCrae SI, Stevens VJ, et al. Distribution of beta-glucosidase and
beta-glucuronidase activity and of beta-glucuronidase gene gus in human colonic
bacteria. FEMS Microbiol Ecol 2008;66:487–95.
25 Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium
thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156–9.
26 Cortes A, Brown MA. Promise and pitfalls of the Immunochip. Arthritis Res Ther
2011;13:101.
27 Crouch DJ, Goddard GH, Lewis CM. REGENT: a risk assessment and classiﬁcation
algorithm for genetic and environmental factors. Eur J Hum Genet
2013;21:109–11.
28 Goddard GH, Lewis CM. Risk categorization for complex disorders according to
genotype relative risk and precision in parameter estimates. Genet Epidemiol
2010;34:624–32.
29 Mahmood A, Fitzgerald AJ, Marchbank T, et al. Zinc carnosine, a health food
supplement that stabilises small bowel integrity and stimulates gut repair processes.
Gut 2007;56:168–75.
30 Selby WS, Jewell DP. T lymphocyte subsets in inﬂammatory bowel disease:
peripheral blood. Gut 1983;24:99–105.
31 Mathew CG, Lewis CM. Genetics of inﬂammatory bowel disease: progress and
prospects. Hum Mol Genet 2004;13 Spec No 1:R161–8.
32 Flint HJ, Scott KP, Louis P, et al. The role of the gut microbiota in nutrition and
health. Nat Rev Gastroenterol Hepatol 2012;9:577–89.
33 Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty
acids, regulate colonic Treg cell homeostasis. Science 2013;341:569–73.
34 Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese
and lean twins. Nature 2009;457:480–4.
35 Willing B, Dicksved J, Halfvarson J, et al. A pyrosequencing study in twins shows
that GI microbial proﬁles vary with inﬂammatory bowel disease phenotypes.
Gastroenterology 2010;139:1844–54.
36 Spor A, Koren O, Ley R. Unravelling the effects of the environment and host
genotype on the gut microbiome. Nat Rev Microbiol 2011;9:279–90.
37 Malmborg P, Bahmanyar S, Grahnquist L, et al. Cesarean section and the risk of
pediatric Crohn’s disease. Inﬂamm Bowel Dis 2012;18:703–8.
38 Kieper WC, Troy A, Burghardt JT, et al. Recent immune status determines the source of
antigens that drive homeostatic T cell expansion. J Immunol 2005;174:3158–63.
39 Bargatze RF, Jutila MA, Butcher EC. Distinct roles of L-selectin and integrins alpha
4 beta 7 and LFA-1 in lymphocyte homing to Peyer’s patch-HEV in situ: the
multistep model conﬁrmed and reﬁned. Immunity 1995;3:99–108.
40 Wagner N, Lohler J, Kunkel EJ, et al. Critical role for beta7 integrins in formation of
the gut-associated lymphoid tissue. Nature 1996;382:366–70.
41 Cimbro R, Vassena L, Arthos J, et al. Interleukin-7 induces expression and activation
of integrin alpha4beta7 promoting naive T-cell homing to the intestinal mucosa.
Blood 2012;120:2610–19.
42 Halfvarson J. Genetics in twins with Crohn’s disease: less pronounced than
previously believed? Inﬂamm Bowel Dis 2011;17:6–12.
43 Tysk C, Lindberg E, Jarnerot G, et al. Ulcerative colitis and Crohn’s disease in an
unselected population of monozygotic and dizygotic twins. A study of heritability
and the inﬂuence of smoking. Gut 1988;29:990–6.
1586 Hedin CR, et al. Gut 2014;63:1578–1586. doi:10.1136/gutjnl-2013-306226
Inﬂammatory bowel disease
 group.bmj.com on October 6, 2014 - Published by gut.bmj.comDownloaded from 
doi: 10.1136/gutjnl-2013-306226
 2014 63: 1578-1586 originally published online January 7, 2014Gut
 
Charlotte R Hedin, Neil E McCarthy, Petra Louis, et al.
 
siblings
Crohn's disease and their unaffected
cell phenotype are shared by patients with 
Altered intestinal microbiota and blood T
 http://gut.bmj.com/content/63/10/1578.full.html
Updated information and services can be found at: 
These include:
Data Supplement
 http://gut.bmj.com/content/suppl/2014/01/07/gutjnl-2013-306226.DC1.html
"Supplementary Data"
References
 http://gut.bmj.com/content/63/10/1578.full.html#ref-list-1
This article cites 43 articles, 16 of which can be accessed free at:
service
Email alerting
the box at the top right corner of the online article.
Receive free email alerts when new articles cite this article. Sign up in
Collections
Topic
 (895 articles)Crohn's disease   
 
Articles on similar topics can be found in the following collections
Notes
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on October 6, 2014 - Published by gut.bmj.comDownloaded from 
